Business
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched f...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors\n\n\n\n\n MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective response rate (ORR) benchmarks in these difficult to treat populations\n \n\n\n\n In the monotherapy expansion cohorts, irrespective of tumor type, patients treated with MDNA11, as the next treatment following progression on immune checkpoint inhibitors (ICI), had an ORR of 42% and a disease control rate (DCR) of 83% underscoring potential of MDNA11 in earlier lines of treatment\n \n\n\n\n Monotherapy expansion cohorts demonstrate ORRs of 38% in melanoma and 22% in MSI-H corresponding to DCR of 75% and 78%, respectively\n \n\n\n\n MDNA11 in combination with KEYTRUDA (pembrolizumab) shows ORR and DCR of 50% and 75%, respectively, for MSS endometrial cancer while MSS TMB-H tumors demonstrated ORR and DCR of 25% and 88%, respectively\n \n\n\n\n Monotherapy and combination treatment achieve durable responses in multiple advanced metastatic tumors, including pancreatic, breast, colorectal, endometrial, bladder, anal cancer and melanoma\n \n\n\n\n Tumor control (responders and those with stable disease) was associated with significantly prolonged median overall survival (mOS) in both monotherapy and combination cohorts\n \n\n\n\n Medicenna will host a webinar with its management team and the presenting Principal Investigator along with commentary from key opinion leaders to discuss the updated data\n \n\n\n TORONTO and HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today presented updated clinical data from the ongoing Phase 1/2 ABILITY-1 study evaluating MDNA11 in patients with advanced solid tumors at the European Society of Medical Oncology (ESMO) Immuno-Oncology Congress 2025. MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, is being evaluated as a monotherapy or in combinati...